Intellia Therapeutics Shares Have Struggled, But It's Now Go-Time (Rating Upgrade)

Core Insights - The article discusses the author's transition to independent investment research after over 43 years in the industry, emphasizing a focus on actionable investment insights rather than adhering to external agendas [1] - The author specializes in rules and factor-based equity investing strategies, combining quantitative analysis with fundamental analysis to derive investment stories that predict future performance [1] - The author has extensive experience across various market segments, including large cap, small cap, micro cap, value, growth, and income stocks, as well as managing a high-yield fixed-income fund [1] Group 1 - The author aims to provide the best actionable investment insights without being influenced by any product agenda [1] - The approach taken is to use numbers as a tool to inspire human intelligence-driven investment narratives rather than relying solely on statistical studies [1] - The author has a background in investor education, having conducted seminars and authored books on stock selection and analysis [1] Group 2 - The author has developed and worked with various quantitative models and has experience in quantitative asset allocation strategies, which are foundational to modern Robo Advising [1] - The article highlights the author's previous roles, including editing stock newsletters and serving as an assistant research director at Value Line [1] - The author expresses openness to feedback and criticism from readers, indicating a willingness to engage with the investment community [1]